Avara Management Ltd
CIK: 0001814934
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 65,803 | $1.8M | 12/29/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 209,863 | $5.9M | 12/28/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 41,729 | $1.2M | 12/27/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 10,229 | $286K | 12/15/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 364,441 | $10.5M | 12/14/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 307,935 | $8.9M | 12/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.